These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25617930)

  • 1. To treat or not to treat? Questions, controversies in prevention.
    Caffrey MK
    Am J Manag Care; 2014 May; 20(8 Spec No.):E11. PubMed ID: 25617930
    [No Abstract]   [Full Text] [Related]  

  • 2. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
    Scherer DJ; Nicholls SJ
    Vasc Health Risk Manag; 2015; 11():203-9. PubMed ID: 25848301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
    Kim ES; McCormack PL
    Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of cardiovascular risk with icosapent ethyl (Vascepa).
    Med Lett Drugs Ther; 2020 Feb; 62(1591):17-18. PubMed ID: 32022786
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial.
    Sheikh O; Vande Hei AG; Battisha A; Hammad T; Pham S; Chilton R
    Cardiovasc Diabetol; 2019 Jun; 18(1):84. PubMed ID: 31234885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination lipid therapy in type 2 diabetes.
    Perkins WJ
    N Engl J Med; 2010 Aug; 363(7):694; author reply 694-5. PubMed ID: 20842773
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Icosapent ethyl for treatment of elevated triglyceride levels.
    Nelson SD; Munger MA
    Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Authors' reply.
    Ballantyne CM; Bays HE; Braeckman RA; Soni PN
    Am J Cardiol; 2013 Feb; 111(3):455-6. PubMed ID: 23317532
    [No Abstract]   [Full Text] [Related]  

  • 13. ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol.
    Baum SJ
    Am J Cardiol; 2013 Feb; 111(3):454-5. PubMed ID: 23317530
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.
    Miller M
    Future Cardiol; 2019 Nov; 15(6):391-394. PubMed ID: 31524535
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessing the clinical benefits of lipid-disorder drugs.
    Hiatt WR; Smith RJ
    N Engl J Med; 2014 Jan; 370(5):396-9. PubMed ID: 24476429
    [No Abstract]   [Full Text] [Related]  

  • 17. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
    Braeckman RA; Manku MS; Bays HE; Stirtan WG; Soni PN
    Prostaglandins Leukot Essent Fatty Acids; 2013 Sep; 89(4):195-201. PubMed ID: 23992935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
    J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story.
    Rhainds D; Brodeur MR; Tardif JC
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1059-1079. PubMed ID: 31752565
    [No Abstract]   [Full Text] [Related]  

  • 20. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.